OncoQR ML GmbH products

OQR300: to a 3rd blockbuster-clinically validated target (not disclosed)

OQR400: to a 4th blockbuster-clinically validated target (not disclosed)

Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle strategies.

Lead candidate TYG100 (formerly OQR100, out-licensed to TYG oncology Ltd.) is an “Active Checkpoint Control Immunotherapy (ACCI)” for the treatment of gastroenterological cancers such as pancreatic, stomach, colon, and gastro-esophageal cancer. The immunogen of TYG100 contains a small part of G17 (little gastrin).

Lead candidate OQR200 is a new candidate against HER2/neu, the by far best characterized and clinically validated target to treat breast cancer indications. A reversible induction of HER2/neu specific antibodies has been demonstrated. In vitro, the immune response induced by OQR200 has been shown to have superior efficacy in a direct side by side comparison with successful clinical products (Herceptin/Perjeta).TYG oncology Ltd. has an option on this target under the name TYG200.